Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829906 | 0.92 | UTS2R (0.43) | LMNAMAPTSLC6A4 | |
| SCHEMBL4832418 | 0.90 | OPRM1 (0.49) | OPRM1OPRD1OPRK1LMNAPOLB | |
| SCHEMBL14279614 | 0.83 | UTS2R (0.43) | LMNAMAPTSLC6A4 | |
| SCHEMBL4824981 | 0.83 | UTS2R (0.43) | OPRM1OPRD1OPRK1LMNAMAPT | |
| SCHEMBL4832111 | 0.83 | NPC1 (0.39) | LMNAMAPTSLC6A4 | |
| SCHEMBL4825855 | 0.82 | UTS2R (0.57) | LMNAMAPTSLC6A4 | |
| SCHEMBL14279613 | 0.82 | TSHR (0.52) | LMNAMAPTSLC6A4 | |
| SCHEMBL4828224 | 0.82 | KDR (0.42) | OPRM1OPRD1OPRK1LMNAMAPT | |
| SCHEMBL4632717 | 0.81 | TSHR (0.51) | LMNAMAPTSLC6A4 | |
| SCHEMBL4828129 | 0.81 | DRD2 (0.41) | OPRM1OPRD1OPRK1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | OPRM1 615/4885OPRD1 550/4885OPRK1 268/4885 |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | OPRM1 615/4885OPRD1 550/4885OPRK1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.